文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

重型β地中海贫血亲缘与非亲缘供者移植:国际调查结果

Related and unrelated donor transplantation for β-thalassemia major: results of an international survey.
PubMed 文献 · Blood Adv · 2019-01-01

该国际调查纳入2000至2016年间1110例≤25岁重型β地中海贫血移植患者,评估不同供者类型与年龄对生存的影响。结果显示≤6岁患者及HLA全合亲缘或非亲缘供者移植的总体与无事件生存最高,HLA全合亲缘与非亲缘供者间无差异。结论建议若考虑移植应尽早(≤6岁),无HLA全合亲缘供者时HLA全合非亲缘供者可作为合适替代。

要点

  • ≤6岁患者5年总体生存90%,7-15岁84%,16-25岁63%(P<.001)。
  • HLA全合亲缘与非亲缘供者移植的总体与无事件生存无差异。
  • 无HLA全合亲缘供者时,HLA全合非亲缘供者可作为合适替代。

核心结论

  • 若考虑移植应尽早(年龄≤6岁),HLA全合非亲缘供者可作为无HLA全合亲缘供者时的合适替代。

研究设计与样本

  • 国际调查纳入2000至2016年间1110例≤25岁重型β地中海贫血移植患者。
  • 供者类型包括HLA全合亲缘(n=677;61%)、HLA不合亲缘(n=78;7%)、HLA全合非亲缘(n=252;23%)和HLA不合非亲缘(n=103;9%)。

主要发现

  • ≤6岁、7-15岁、16-25岁患者调整供者类型和预处理方案后的5年总体生存概率分别为90%、84%、63%(P<.001)。
  • 对应5年无事件生存概率分别为86%、80%、63%(P<.001)。
  • HLA全合亲缘与HLA全合非亲缘供者移植的总体生存(89% vs 87%)和无事件生存(86% vs 82%)无差异。
  • HLA不合亲缘与HLA不合非亲缘供者移植的总体生存分别为73% vs 83%,无事件生存分别为70% vs 78%。

临床怎么用

  • 重型β地中海贫血患者若考虑移植,应尽早(年龄≤6岁)进行。
  • 无HLA全合亲缘供者时,可选择HLA全合非亲缘供者作为替代。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We studied 1110 patients with β-thalassemia major aged ≤25 years who received transplants with grafts from HLA-matched related (n = 677; 61%), HLA-mismatched related (n = 78; 7%), HLA-matched unrelated (n = 252; 23%), and HLA-mismatched unrelated (n = 103; 9%) donors between 2000 and 2016. Ninety percent of transplants were performed in the last decade. Eight-five percent of patients received ≥20 transfusions and 88% were inadequately chelated. All patients received myeloablative-conditioning regimen. Overall and event-free survival were highest for patients aged ≤6 years and after HLA-matched related and HLA-matched unrelated donor transplantation. The 5-year probabilities of overall survival for patients aged ≤6 years, 7 to 15 years, and 16 to 25 years, adjusted for donor type and conditioning regimen were 90%, 84%, and 63%, respectively (P < .001). The corresponding probabilities for event-free survival were 86%, 80%, and 63% (P < .001). Overall and event-free survival did not differ between HLA-matched related and HLA-matched unrelated donor transplantation (89% vs 87% and 86% vs 82%, respectively). Corresponding probabilities after mismatched related and mismatched unrelated donor transplantation were 73% vs 83% and 70% vs 78%. In conclusion, if transplantation is considered as a treatment option it should be offered early (age ≤6 years). An HLA-matched unrelated donor is a suitable alternative if an HLA-matched relative is not available.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Li C, Mathews V, Kim S, et al. Related and unrelated donor transplantation for β-thalassemia major: results of an international survey. Blood Adv. 2019. PMID: 31471325. doi:10.1182/bloodadvances.2019000291

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。